About Skye Bioscience, Inc.
https://skyebioscience.comSkye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100, which is in Phase I trials for the treatment of glaucoma and ocular hypertension.
CEO
Punit S. Dhillon
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2023-09-08 | Reverse | 1:250 |
ETFs Holding This Stock
Summary
Showing Top 2 of 12
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
5AM VENTURE MANAGEMENT, LLC
Shares:9.68M
Value:$9.88M
VERSANT VENTURE MANAGEMENT, LLC
Shares:2.01M
Value:$2.05M
BAKER BROS. ADVISORS LP
Shares:1.45M
Value:$1.48M
Summary
Showing Top 3 of 63
About Skye Bioscience, Inc.
https://skyebioscience.comSkye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100, which is in Phase I trials for the treatment of glaucoma and ocular hypertension.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $13.26M ▼ | $-12.75M ▲ | 0% | $-0.32 ▲ | $-12.58M ▲ |
| Q2-2025 | $0 | $18.24M ▲ | $-17.62M ▼ | 0% | $-0.44 ▼ | $-17.43M ▼ |
| Q1-2025 | $0 | $11.76M ▲ | $-11.1M ▼ | 0% | $-0.28 ▼ | $-10.92M ▼ |
| Q4-2024 | $0 | $10.67M ▲ | $-9.75M ▼ | 0% | $-0.24 ▼ | $-9.62M ▼ |
| Q3-2024 | $0 | $4.97M | $-3.9M | 0% | $-0.1 | $-3.54M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $35.31M ▼ | $41.32M ▼ | $8.49M ▲ | $32.84M ▼ |
| Q2-2025 | $48.59M ▼ | $52.16M ▼ | $8.48M ▲ | $43.68M ▼ |
| Q1-2025 | $59.22M ▼ | $64.79M ▼ | $5.54M ▲ | $59.25M ▼ |
| Q4-2024 | $68.42M ▲ | $72.76M ▼ | $4.61M ▼ | $68.15M ▼ |
| Q3-2024 | $67.41M | $81.54M | $5.73M | $75.8M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-12.75M ▲ | $-13.36M ▼ | $7.97M ▲ | $0 ▼ | $-5.4M ▲ | $-13.36M ▼ |
| Q2-2025 | $-17.62M ▼ | $-10.75M ▲ | $-11.86M ▲ | $18.16K ▲ | $-22.58M ▲ | $-10.75M ▲ |
| Q1-2025 | $-11.1M ▼ | $-9.19B ▼ | $-12.81B ▼ | $0 ▼ | $-21.99B ▼ | $-9.19B ▼ |
| Q4-2024 | $-9.75M ▼ | $-8.17M ▼ | $90.41K ▲ | $5.62K ▲ | $-8.08M ▼ | $-8.22M ▼ |
| Q3-2024 | $-3.9M | $-5.26M | $-1.45M | $0 | $-6.71M | $-6.78M |
CEO
Punit S. Dhillon
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2023-09-08 | Reverse | 1:250 |
ETFs Holding This Stock
Summary
Showing Top 2 of 12
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
5AM VENTURE MANAGEMENT, LLC
Shares:9.68M
Value:$9.88M
VERSANT VENTURE MANAGEMENT, LLC
Shares:2.01M
Value:$2.05M
BAKER BROS. ADVISORS LP
Shares:1.45M
Value:$1.48M
Summary
Showing Top 3 of 63